Lidocain-Egis

Lidocaine, the active ingredient in Lidocain-Egis, is a local anesthetic presented as a topical formulation for skin application. It is used to provide local anesthesia and pain relief for minor procedures and certain neuropathic pain conditions in adults. GNH USA supplies Lidocain-Egis as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidocain-Egis is a topical local anesthetic used to block nerve transmission in the skin and superficial tissues. - Skin procedures: provides rapid local anesthesia for minor surgical or diagnostic interventions. - Minor injury pain: reduces pain from cuts, abrasions, or burns during first‑aid treatment. - Neuropathic pain (topical): alleviates localized neuropathic discomfort such as post‑herpetic neuralgia when applied to the affected area.

Lidocain-Egis may cause a range of adverse reactions after topical application.

Common Side Effects: - Burning or stinging sensation at the application site. - Redness or mild erythema of the skin. - Itching or mild rash localized to the treated area.

Serious or Rare Side Effects: - Allergic reaction: hives, swelling, or difficulty breathing. - Systemic toxicity: dizziness, seizures, or cardiac arrhythmia if absorbed in large amounts. - Severe skin irritation or ulceration at the site of application.

Before using Lidocain-Egis, consider the following safety measures. - Assess allergy: verify the patient has no known hypersensitivity to lidocaine or related anesthetics. - Limit area: apply only to the recommended surface area and avoid excessive layering. - Avoid mucous membranes: do not use on eyes, mouth, or other mucosal surfaces unless specifically directed. - Cardiac caution: use with care in patients with known conduction disorders or heart block. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lidocain-Egis can interact with other medicines that affect cardiac conduction or drug metabolism.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): additive risk of cardiac toxicity. - Beta‑blockers (e.g., propranolol): may enhance lidocaine’s cardiodepressive effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): may increase systemic lidocaine levels. - CYP1A2 inducers (e.g., carbamazepine, rifampin): may reduce lidocaine effectiveness. - Concurrent use of other local anesthetics: risk of cumulative systemic toxicity.